Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01928394

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors

Sponsor: Bristol-Myers Squibb

Conditions Advanced or Metastatic Solid Tumors

Interventions Cobimetinib Ipilimumab Nivolumab

Updated 26 times since 2017 Last updated: Dec 9, 2024 Started: Oct 24, 2013 Primary completion: Feb 5, 2019 Completion: Nov 18, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced or Metastatic Solid Tumors and is currently completed. Bristol-Myers Squibb leads this study, which shows 26 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

26 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Jan 2025 — Sep 2025 [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 21 earlier versions

Feb 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jul 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2021 — May 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2017 — Nov 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain , Bologna, Italy , Bonn, Germany , Boston, United States , Charlotte, United States , Copenhagen, Denmark , Durham, United States and 25 more locations